Investment
Features
FeesSafety
Academy
More
Pluang+

Compare National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) vs Viatris Inc (VTRS) Price & Performance

National Grid Transco PLC National Grid PLC (NEW) American Depositary SharesTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares vs Viatris Inc — how do they compare? National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $78.5 (market cap $78.25B), while Viatris Inc trades at $17.56 (market cap $19.81B). The key difference: National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares is far larger — about 4× Viatris Inc's market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays the higher dividend (4.14%). Which is the better fit depends on your goals.

NGGVTRS
Market Cap
$78.25B$19.81B
Volume
1,070,0317,547,542
Sector
UtilitiesHealth
52-Week High
$93.93$18.27
52-Week Low
$73.54$9.98
Enterprise Value
$136.28B$31.92B
Dividend Yield
4.14%2.78%
Typical Hold Time
—57 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares

National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.

Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $3.51B in 2025. Recent news highlights include FDA approval for WAKIX in Japan and recognition as a top employer. Analyst consensus is mixed with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but faces fundamental challenges including negative profit margins and high debt. Positive cash flow generation and consistent earnings beats provide support, while competitive pressures and execution risks remain concerns for investors seeking turnaround potential in the healthcare sector.

Returns comparison

Trailing returns across standard periods

About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares

National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.

Read more on NGG →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →